MTHFR Gene Mutations: A Potential Marker of Late-Onset Alzheimer's Disease?

J Alzheimers Dis. 2015;47(2):323-7. doi: 10.3233/JAD-150304.

Abstract

Recent epigenome-wide association studies have confirmed the importance of epigenetic effects mediated by DNA methylation in late-onset Alzheimer's disease (LOAD). Metabolic folate pathways and methyl donor reactions facilitated by B-group vitamins may be critical in the pathogenesis of LOAD. Methylenetetrahydrofolate reductase (MTHFR) gene mutations were studied in consecutive Alzheimer's Disease & Memory Clinic patients up to December 2014. DNA analyses of MTHFR-C667T and - A1298C homozygous and heterozygous polymorphisms in 93 consecutive elderly patients revealed high prevalence of MTHFR mutations (92.5%). Findings require confirmation in a larger series, but MTHFR mutations may become a LOAD marker, opening novel possibilities for prevention and treatment.

Keywords: Alzheimer’s disease; DNA methylation; MTHFR gene; epigenetics; vitamins B-group.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age of Onset
  • Aged
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / epidemiology*
  • Alzheimer Disease / genetics*
  • Cohort Studies
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Mutation*
  • Prevalence
  • Prognosis

Substances

  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)